Unstable Angina Pectoris

Also known as: Angina Pectoris, Unstable / Angina Unstable / Unstable Angina (UA) / Angina, Unstable / Unstable Angina / Accelerated angina / Intermediate coronary syndrome / Angina pectoris unstable / Angina at rest / Crescendo angina / Angina worsened

DrugDrug NameDrug Description
DB00945Acetylsalicylic acidAlso known as _Aspirin_, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) [FDA label]. Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer [A177325]. Aspirin is classified as a _non-selective cyclooxygenase (COX) inhibitor_ [A32682, A177268] and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others [L5968]. Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants [FDA label].
DB09302AlirocumabAlirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of diet and statin treatment. It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval. The FDA approval was contingent on the completion of further clinical trials to better determine efficacy and safety. PCSK9 inhibition facilitates more LDL-C clearance from the blood.
DB00758ClopidogrelClopidogrel, an antiplatelet agent structurally and pharmacologically similar to ticlopidine, is used to inhibit blood clots in a variety of conditions such as peripheral vascular disease, coronary artery disease, and cerebrovascular disease. Clopidogrel is sold under the name Plavix by Sanofi and Bristol-Myers Squibb. The drug is an irreversible inhibitor of the P2Y12 adenosine diphosphate receptor found on the membranes of platelet cells. Clopidogrel use is associated with several serious adverse drug reactions such as severe neutropenia, various forms of hemorrhage, and cardiovascular edema.
DB06779DalteparinDalteparin, a low molecular weight heparin (LMWH) prepared by nitrous acid degradation of unfractionated heparin of porcine intestinal mucosa origin, is an anticoagulant. It is composed of strongly acidic sulphated polysaccharide chains with an average molecular weight of 5000 and about 90% of the material within the range of 2000-9000. LMWHs have a more predictable response, a greater bioavailability, and a longer anti-Xa half life than unfractionated heparin. Dalteparin can also be safely used in most pregnant women. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
DB00569FondaparinuxFondaparinux (Arixtra) is a synthetic anticoagulant agent consisting of five monomeric sugar units and a O-methyl group at the reducing end of the molecule. It is structurally similar to polymeric glycosaminoglycan heparin and heparan sulfate (HS) when they are cleaved into monomeric units. The monomeric sequence in heparin and HS is thought to form the high affinity binding site for the natural anti-coagulant factor, antithrombin III (ATIII). Once bound to heparin or HS, the anticoagulant activity of ATIII is potentiated by 1000-fold. Fondaparinux potentiates the neutralizing action of ATIII on activated Factor X 300-fold. Fondaparinux may be used: to prevent venous thromboembolism in patients who have undergone orthopedic surgery of the lower limbs (e.g. hip fracture, hip replacement and knee surgery); to prevent VTE in patients undergoing abdominal surgery who are are at high risk of thromboembolic complications; in the treatment of deep vein thrombosis (DVT) and pumonary embolism (PE); in the management of unstable angina (UA) and non-ST segment elevation myocardial infarction (NSTEMI); and in the management of ST segment elevation myocardial infarction (STEMI).
DB01109HeparinUnfractionated heparin (UH) is a heterogenous preparation of anionic, sulfated glycosaminoglycan polymers with weights ranging from 3000 to 30,000 Da. It is a naturally occurring anticoagulant released from mast cells. It binds reversibly to antithrombin III (ATIII) and greatly accelerates the rate at which ATIII inactivates coagulation enzymes thrombin (factor IIa) and factor Xa. UH is different from low molecular weight heparin (LMWH) in the following ways: the average molecular weight of LMWH is about 4.5 kDa whereas it is 15 kDa for UH; UH requires continuous infusions; activated partial prothrombin time (aPTT) monitoring is required when using UH; and UH has a higher risk of bleeding and higher risk of osteoporosis in long term use. Unfractionated heparin is more specific than LMWH for thrombin. Furthermore, the effects of UH can typically be reversed by using protamine sulfate.
DB08813NadroparinNadroparin is a low molecular weight heparin (LMWH) which, when bound to antithrombin III (ATIII), accelerates the inactivation of factor II and factor Xa. Nadroparin halts the coagulation pathway by inhibiting the activation of thrombin (factor IIa) by factor Xa. The amplification of the fibrin clotting cascade is stopped once factors Xa and IIa are inactivated. It is derived from porcine sources and has a mean molecular size of 5000 daltons. Low molecular weight heparins are less effective at inactivating factor IIa due to their shorter length compared to unfractionated heparin.
DB00775TirofibanTirofiban prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
DB00661VerapamilA calcium channel blocker that is a class IV anti-arrhythmia agent.
DrugDrug NameTargetType
DB00945Acetylsalicylic acidProstaglandin G/H synthase 1target
DB00945Acetylsalicylic acidProstaglandin G/H synthase 2target
DB00945Acetylsalicylic acidAldo-keto reductase family 1 member C1target
DB00945Acetylsalicylic acidSolute carrier family 22 member 6transporter
DB00945Acetylsalicylic acidMultidrug resistance protein 1transporter
DB00945Acetylsalicylic acidCytochrome P450 2C19enzyme
DB00945Acetylsalicylic acidCytochrome P450 2C9enzyme
DB00945Acetylsalicylic acid5'-AMP-activated protein kinasetarget
DB00945Acetylsalicylic acidEndothelin-1 receptortarget
DB00945Acetylsalicylic acidNuclear factor kappa b beta subunittarget
DB00945Acetylsalicylic acidCellular tumor antigen p53target
DB00945Acetylsalicylic acid78 kDa glucose-regulated proteintarget
DB00945Acetylsalicylic acidRibosomal protein S6 kinase alpha-3target
DB00945Acetylsalicylic acidNF-kappa-B inhibitor alphatarget
DB00945Acetylsalicylic acidTumor necrosis factor-inducible gene 6 proteintarget
DB00945Acetylsalicylic acidCaspase-1target
DB00945Acetylsalicylic acidCaspase-3target
DB00945Acetylsalicylic acidInhibitor of nuclear factor kappa-B kinase subunit betatarget
DB00945Acetylsalicylic acidExtracellular signal-regulated kinase (ERK)target
DB00945Acetylsalicylic acidG1/S-specific cyclin-D1target
DB00945Acetylsalicylic acidMyc proto-oncogene proteintarget
DB00945Acetylsalicylic acidProliferating cell nuclear antigentarget
DB00945Acetylsalicylic acidCyclin Atarget
DB00945Acetylsalicylic acidUDP-glucuronosyltransferase 1-6enzyme
DB00945Acetylsalicylic acidArylamine N-acetyltransferase 2enzyme
DB00945Acetylsalicylic acidSolute carrier family 22 member 8transporter
DB09302AlirocumabProprotein convertase subtilisin/kexin type 9target
DB00758ClopidogrelP2Y purinoceptor 12target
DB00758ClopidogrelCytochrome P450 3A4enzyme
DB00758ClopidogrelCytochrome P450 2B6enzyme
DB00758ClopidogrelCytochrome P450 3A5enzyme
DB00758ClopidogrelCytochrome P450 2C19enzyme
DB00758ClopidogrelCytochrome P450 2C9enzyme
DB00758ClopidogrelCytochrome P450 1A2enzyme
DB00758ClopidogrelCytochrome P450 2C8enzyme
DB00758ClopidogrelLiver carboxylesterase 1enzyme
DB00758ClopidogrelMultidrug resistance protein 1transporter
DB00758ClopidogrelSolute carrier family 22 member 1transporter
DB00758ClopidogrelSolute carrier family 22 member 2transporter
DB06779DalteparinVascular endothelial growth factor Atarget
DB06779DalteparinTissue factor pathway inhibitortarget
DB00569FondaparinuxCoagulation factor Xtarget
DB01109HeparinCoagulation factor Xtarget
DB01109HeparinFibroblast growth factor receptor 4target
DB01109HeparinFibroblast growth factor 4target
DB01109HeparinFibroblast growth factor 19target
DB01109HeparinFibroblast growth factor receptor 1target
DB01109HeparinFibroblast growth factor 1target
DB01109HeparinFibroblast growth factor receptor 2target
DB01109HeparinFibroblast growth factor 2target
DB01109HeparinPlatelet factor 4target
DB01109HeparinHepatocyte growth factortarget
DB01109HeparinThyroxine-binding globulincarrier
DB08813NadroparinProto-oncogene c-Fostarget
DB08813NadroparinMyc proto-oncogene proteintarget
DB00775TirofibanIntegrin alpha-IIbtarget
DB00775TirofibanIntegrin beta-3target
DB00661VerapamilSodium channel protein type 5 subunit alphatarget
DB00661VerapamilATP-sensitive inward rectifier potassium channel 11target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-4target
DB00661VerapamilVoltage-dependent T-type calcium channel subunit alpha-1Gtarget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Ftarget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-3target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Dtarget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-1target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit beta-2target
DB00661VerapamilPotassium voltage-gated channel subfamily H member 2target
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Starget
DB00661VerapamilVoltage-dependent L-type calcium channel subunit alpha-1Ctarget
DB00661VerapamilVoltage-dependent T-type calcium channel subunit alpha-1Itarget
DB00661VerapamilCytochrome P450 1A2enzyme
DB00661VerapamilCytochrome P450 3A5enzyme
DB00661VerapamilVoltage-dependent N-type calcium channel subunit alpha-1Btarget
DB00661VerapamilVoltage-dependent P/Q-type calcium channel subunit alpha-1Atarget
DB00661VerapamilSodium-dependent serotonin transportertarget
DB00661VerapamilCytochrome P450 3A4enzyme
DB00661VerapamilCytochrome P450 3A7enzyme
DB00661VerapamilMultidrug resistance protein 1transporter
DB00661VerapamilSolute carrier family 22 member 1transporter
DB00661VerapamilCanalicular multispecific organic anion transporter 2transporter
DB00661VerapamilMultidrug resistance-associated protein 4transporter
DB00661VerapamilSolute carrier family 22 member 5transporter
DB00661VerapamilMultidrug resistance-associated protein 1transporter
DB00661VerapamilSolute carrier organic anion transporter family member 1A2transporter
DB00661VerapamilMultidrug resistance-associated protein 7transporter
DB00661VerapamilCanalicular multispecific organic anion transporter 1transporter
DB00661VerapamilSolute carrier family 22 member 4transporter
DB00661VerapamilATP-binding cassette sub-family G member 2transporter
DB00661VerapamilSolute carrier organic anion transporter family member 1B1transporter
DB00661VerapamilCytochrome P450 2C8enzyme
DB00661VerapamilCytochrome P450 2C9enzyme
DB00661VerapamilCytochrome P450 2C18enzyme
DB00661VerapamilCytochrome P450 2B6enzyme
DB00661VerapamilCytochrome P450 2C19enzyme
DB00661VerapamilCytochrome P450 2D6enzyme
DB00661VerapamilAlpha-1A adrenergic receptortarget
DB00661VerapamilAlpha-1B adrenergic receptortarget
DB00661VerapamilAlpha-1D adrenergic receptortarget
DB00661VerapamilBile salt export pumptransporter
DrugDrug NamePhaseStatusCount
DB01076Atorvastatin2Unknown Status1
DB09106Hydroxyethyl Starch2Completed1
DB00945Acetylsalicylic acid3Completed1
DB09341Dextrose, unspecified form3Completed1
DB11133Omega-3 fatty acids3Completed1
DB05399Succinobucol3Unknown Status1
DB00163Vitamin E3Completed1
DB00945Acetylsalicylic acid4Recruiting1
DB01076Atorvastatin4Unknown Status1
DB11121Chloroxylenol4Active Not Recruiting1
DB00758Clopidogrel4Active Not Recruiting1
DB06695Dabigatran etexilate4Withdrawn1
DB09220Nicorandil4Unknown Status1
DB09153Sodium chloride4Recruiting1
DB00945Acetylsalicylic acidNot AvailableWithdrawn1
DB00009AlteplaseNot AvailableWithdrawn1
DB00758ClopidogrelNot AvailableWithdrawn1
DB00633DexmedetomidineNot AvailableCompleted1
DB01225EnoxaparinNot AvailableWithdrawn1
DB00281LidocaineNot AvailableCompleted1
DB00086StreptokinaseNot AvailableWithdrawn1